While ERT provides significant benefits, it also has limitations. One of the main challenges is that the recombinant enzymes often have difficulty crossing the blood-brain barrier, which limits their effectiveness in treating neurological symptoms. Additionally, ERT can be expensive and may require lifelong treatment. Patients may also develop an immune response to the recombinant enzyme, which can reduce its efficacy.
